A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 124 participants.
Also called NCT02331680
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 124 participants
- Registry
-
NCT02331680
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02331680. Randomized; double masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-05 (actual). Results posted on 2019-10-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
- Condition
- Chronic Renal Failure
- Intervention (Drug)
- OPC-41061
- Intervention (Drug)
- OPC-41061
- Intervention (Drug)
- Placebo
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct02331680- Content hash
1d1cf88b18dc5bdf92f8c862686398aca46eafd8bd442432f96881edfd1d6a8f